Company intelligence / Profile preview
AI Proteins
Boston, Massachusetts, United States
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
AI Proteins is advancing a pipeline of de novo designed miniprotein therapeutics, with internal programs in oncology in pre-clinical stages, and has collaborations targeting inflammation and metabolic diseases[1][2][5]. No clinical data have been publicly disclosed as of August 2025.
- Therapeutic areas
- OncologyMetabolic DisordersImmunology
- Modalities
- ProteinPeptidesMiniprotein (de novo designed)Biologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on AI Proteins.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AI Proteins.